Bone marrow chromosome karyotype analysis

When it comes to leukemia, most people are familiar with it. Everyone knows that suffering from leukemia is generally equivalent to sentencing one's life to death. However, with the advancement of medicine, medical technology is also constantly developing and changing. In fact, if leukemia undergoes professional and formal treatment, most leukemias can be well controlled. Bone marrow chromosome karyotype analysis technology is currently a common method for treating leukemia.

The so-called chromosome karyotype analysis refers to the process of artificially pairing, numbering and grouping the chromosomes of the cells to be tested according to the inherent chromosome morphological and structural characteristics of the organism and certain regulations, and performing morphological analysis. By applying chromosome karyotype analysis technology to the study of blood diseases, through the classification and analysis of chromosomes, we can fully detect important indicators of disease changes, classify leukemia well, and accurately diagnose and identify different types of leukemia, so as to find the specific causes of different patients' diseases and determine specific treatment plans based on each person, effectively avoiding blind treatment and causing irreversible consequences.

The treatment of leukemia is mainly based on combined chemotherapy of varying intensities. An indiscriminate chemotherapy model may not be appropriate for every patient. The chromosome analysis technology can evaluate the prognosis risk of different leukemias, or even the same type of leukemia, to facilitate the implementation of more perfect personalized treatment. This can reduce the number of chemotherapy and intensive treatments for low-risk patients, alleviate the financial pressure on patients, greatly improve their quality of life, and reduce overtreatment. On the other hand, this technology can also select high-risk patients in advance, and arrange stem cell transplantation treatment in a timely manner after trying new drugs or chemotherapy relief.

With the promotion and application of chromosome karyotype analysis technology, chromosome karyotype has become the most valuable independent prognostic factor for blood diseases, which has guiding significance for the selection of treatment plans. At the same time, chromosome aberration can also be used as an important reference indicator for detecting disease remission and recurrence.

Except for chronic myeloid leukemia, acute leukemia and chronic lymphocytic leukemia have a variety of different prognostic indicators. According to different indicators, these patients can be divided into different prognostic levels and different intensities of treatment can be adopted. Therefore, as modern medicine's understanding of leukemia becomes more and more detailed, all patients should complete the comprehensive examinations required for various prognostic stratifications as much as possible after diagnosis, and then develop an individualized treatment plan. Among these prognostic indicators, chromosomal and various gene abnormalities are the most important.

Bone marrow chromosome karyotype analysis technology is not only for leukemia, but also for common blood diseases, congenital diseases, and patients who have acquired diseases due to exposure to poisons, radiation, chemotherapy drugs, etc. should also undergo routine screening to determine whether there is a risk of tumor development.